绿叶制药：截至2026年6月30日止六个月之中期业绩公告

LUYE PHARMA GROUP LTD. 02186 2026630 •2025630179.05.6%3,002.1•2025630255.311.8%1,902.363.4%•202563023.46.5%380.8•202563077.624.8%390.5•EBITDA202563047.03.9%1,251.2•9.7820256308.32•2026630 20266302025 63020262025 380,799357,383 129,49168,464 2026630 1. 20266303420251231 2. 20251231 97 11179107 (a)9720261231 (b)111779107 3. 4. 630202620253,002,0793,181,110 5. 6. 7. 20262025630 2026630 2026630202615% 8. 20266302025630 9. 3,994,515,95320253,761,670,643 *100,202,0003,917,139,202 2026630927,831,0002025123197,974,0002026630252,545,00020251231313,484,000 20266301,029,044,00020251231 2026630370,613,00020251231506,347,000 2026630 (a) (i)308,152,00020251231225,792,000(ii)717,869,00020251231741,541,000(iii)26,403,0002025123127,252,000(iv) (b) (i)384,222,00020251231236,710,000(ii)1,029,044,00020251231(iii)(iv) 13. 2023 202376180,000,0006.25%20238162028764.882026762028766.25%1676 202661189,740,000100.00%202663090,260,000 20231231 20241231 20251231 2026 2026610180,000,0005.25%202761020316102.71203161020316105.25%6101210 1,226,340(62,749)(990)(18,065) 2026630 14. (a) (i)2,9504,197(i)4,6713,185 (ii)–1,483 (iii)1,2361,915 (iii)581660 (iii)3,3521,419 (iv)1,3492,881 (iv)5675,621 (i)(ii)(iii)(iv) (b) 495,000,000 (c) 149,359477,971 *2,8213,030 ***18,939,000202517,523,00030,461,000202525,976,000#20251231LPVC2026 8GMP5080 2026630 IQVIA65322 ErzofriRykindoLY30410 22.2%1,059.85.9%734.26.7%192.224.0%180.035.5%835.9 18 BA1101VEGF®202146mCRC20255BLA (ADT)NASDAQBGNE06160688235 202412SCLCCSCO2025SCLCINCCNESMOSCLC2025 2020FDA199729FDASCLC 120266302009 202462025 IR50 202211120261GAD 20211Rykindo20231FDAI Erzofri Erzofri20247505(b)(2)505(b)(2)FDA202311,666,5732039 (II)2025 20246 2026630IQVIA202694IQVIA2026 IQVIA2026192026 IQVIA2026 2026IQVIA202672026 BA51011(GLP-1)20258220265BA5101220266BA5101BA5101 BA610160mgRANKG2Prolia20221120255202511BA6101MAA20261BA6101AGEMED20265BA6101FDA20267FDA BA9101nAMDDME(RVO)(DR)(mCNV)(ROP)202511nAMDDME1477BA910120268ANVISABA9101nAMDDME ProbodyADC 202663057061280202663024675566118 202663028158515 1 202211(MDD) •20261GAD LY03015VMAT22Sigma-1TDHD AILY03015VMAT2Sigma-1RLY03015VMAT2LY03015(DA)DAD2Sigma-1R, LY03015(BDNF) •20264LY03015(PK)20268LY0301520 mgLY0301512121LY030152(TEAE)(SAE)3TEAE33.3%83.3%LY03015IILY03015 •20266LY03015TDIIIILY03015TD121TD111 15mg10mg20mgLY03015LY030151AIMS25.9%76.5%10 mg20 mg(p<0.01)20 mg76.5%2TD6AIMS1-74(LS)4.04.7(p<0.05)3AIMS32.93.94(SAE)(AE)AEQT LY0301752A5-HT2AR52C5-HT2CRPDPADP(NSS) LY030175-HT2AR5-HT2CRADPPDP ILY03017(TEAE)(PK) , LY03017PK •20264LY03017ADPII LY030201(TAAR1)5-HT2CR LY03020(NCE/NTE)TAAR15-HT2CR1A(5-HT1AR)TAAR1(DA)(5-HT)5-HT2CR5-HT LY03020LY03020(EPS)ILY03020EPS •20264LY03020II BA610160mgRANKG2Prolia 20221120255202511BA6101 •20261BA6101(AGEMED) •20265BA6101(BLA)(FDA)20267FDABLABA6101 BA1102120mgRANKLG2 20245GCTB1≥45kg20265(SRE)20255202511BA1102MAA •20265(SRE) •20265BA1102(BLA)FDA20267FDABLABA1102 BA51011(GLP-1) 202582 •20265BA51012 BA9101 202511nAMDDME •20268(ANVISA)BA9101(BLA)nAMDDME BA1106IL-2CD25 BA1106IL-2CD25IL-2R(ADCC)BA1106CD25TTT(Teff)IL-2 •20264CDEBA1106BA1104NSCLCII20267CDEIIIIBA1106BA1104NSCLC(PK) BA1301Claudin18.2ADC BA1301Claudin18.2ADCC-LockDuostatin-5CLDN18.2ADCBA1301FDAODD •20265BA1301I2026(ASCO)2025122291BA1301(i) BA1301CLDN18.2BA1301≥1.6 mg/kg(ORR)29%30%14%33%(PR)16(ii) BA1301≥34.4%2.2%≥33.3%2.2%(SAE)14.3%(iii) BA1301C-Lock2.0 mg/kgDuostatin-5(AUC)0.002%ADC0.005% BA1302CD228ADC CD228BA1302MMAECD228BA1302FDA(ODD)(sqNSCLC)20256BA1302FDA •20268IIa202681Ia0.2 mg/kg3.6 mg/kg36312.0 mg/kg83.3%66.7%Ia1(PR)PRCD228PR2.0 mg/kgPRPRBA1302(PFS)(OS)2BA1302(TRAE)TRAECTCAE v5.012IaIbBA1302 BA1203PD-1/IL-2 BA1203IOBA1203PD-1/IL-2 BA1203PD-1IL-2TMEIL-2TMEPD-1IL-2PD-1TBA1203 BA1203PD-1TMEPD-1/PD-L1BA1203BA1203BA1203 •20267CDEBA1203(IND) TL1AIL23p19 BA2201BA2201TL1ABA-huMab1+1FcBA2201BA2201BA2201 •20268CDEBA2201(IND) 8050 •20261(BA6101)(AGEMED) •20266ERZOFRIERZOFRI 2026630311,0001,77022,60020266302,32089.5%6,10067.2%14,18065.0% •20265BA51012 •20265BA1102120mg(SRE) •20263 •20263DP Technology(AI4S)ADCTCE •20266BA5101BA5101(BLA) 8GMP2026630 202620251.5%2026202524.8% •BA6101BA1102(BLA)20267FDA2027BA6101BA1102MAA202620261(GAD)(NDA)2027 •BA1104IIIBA1104BLA2026 •LY03015IILY03015III2026LY030172026IILY03017ADPIIA2027LY030202026IILY03020II2027BA1302I2027BA1106BA11042027BA1203IND20267CDE2026BA2201IND20268CDEBA1304IND • Erzofri(NRDL)Erzofri (AI)(CNS)1218 20266303,002.120256303,181.1179.05.6% 2026630835.920256301,295.2459.335.5% 2026630734.22025630693.041.25.9% 2026630192.22025630180.212.06.7% 20266301,059.82025630867.5192.322.2% 2026630180.02025630145.234.824.0% 20256301,023.520266301,099.836.6% 20266301,902.320256302,157.6255.311.8%202563067.8%202663063.4% 2026630456.62025630197.8258.8130.8% 2026630800.220256301,018.8218.621.5%202563032.0%202663026.7% 2026630325.02025630315.59.53.0% 2026630397.92025630213.0184.986.8%